Thirona Retina provides AI-powered software for the analysis of retina images to assist in the diagnosis and efficient screening for eye diseases. The software uses deep learning technology to aid eye care specialists in diagnosing conditions such as Age-related Macular Degeneration and Diabetic Retinopathy.

Thirona Retina

Hospitals and Health Care

Thirona

Thirona Retina | 623 followers on LinkedIn. AI-powered retina image analysis | Thirona Retina BV is a spin-out company of a Dutch based Thirona BV, specializing in the field of AI assisted medical image analysis for eye disease screening, with RetCAD™ as its flagship product platform. 
RetCAD™ is a Class IIa European MDR CE certified software product using artificial intelligence that analyses color fundus images for the presence of Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma. It assists eye care providers in early diagnosis and grading of the vision threatening diseases.

Business Development Manager at Thirona Retina, now an iCare company! | Artificial Intelligence | Ophthalmology | Medical Imaging | Incorporating AI…

Diederik Sakkers

Johanna Ott

What a milestone for both companies! We are very excited to continue our journey together with iCare of Revenio Group Oyj . Together we are stronger and can achieve a lasting impact!

We're #hiring a new Deep Learning Intern in Nijmegen, Gelderland. Apply today or share this post with your network.

We are thrilled to announce that Thirona Retina B.V. has been acquired by iCare Finland Oy, an innovative Finnish company specialized in products for diagnosing and managing ophthalmic diseases. This acquisition marks a significant milestone in our journey to revolutionize ophthalmic image analysis through artificial intelligence. By combining our cutting-edge AI medical device, RetCAD™, with iCare's extensive expertise in the ophthalmic domain, we are poised to provide access to better eyecare to large numbers of patients on a global scale. We will continue to cooperate with our existing customers with even stronger resources. We are excited to embark on this new chapter and look forward to the impactful advancements we will achieve together. https://lnkd.in/eR2SkVse

Diabetic Retinopathy (DR) is a serious health concern for diabetic patients, potentially leading to severe vision loss or blindness, if not diagnosed early. In the Czech Republic, 9.8% of the population is affected by Diabetes as indicated in the latest report of International Diabetes Federation . To enable timely detection of possible first signs of DR to all concerned, our Artificial Intelligence RetCAD software has been included in the national reimbursement program in the Czech Republic. Having trained local eye care providers, in cooperation with @Czech Diabetic Society, we are happy to see the AI-enabled tool being rolled out further, offering quick an accurate diagnosis on-the-spot. Learn more about this initiative and other RetCAD projects: https://lnkd.in/eRGE-jdq . #RetCAD #AI #DiabeticRetinopathy #VisionHealth

National Eye Screening Programs are crucial for ensuring timely care for Diabetic Retinopathy (DR) patients, addressing the challenge of a low doctor-to-patient ratio. Over the past two decades, the number of diabetic patients in Australia has been steadily increasing. As of 2022, 5.3% of the poulation suffers from Diabetes. Delayed access to an on-time diagnosis and treatment is highly prevalent in remote Australian communities. To address this issue, we have partnered with Topcon Healthcare Europe to enable on-the-spot eye screening solutions across Australia. Our Artificial Intelligence powered Software RetCAD, integrated with Topcon's fundus cameras can detect DR quickly and accurately. To know, more about this and our other projects, visit: retcad.eu/projects . #RetCAD #AI #DiabeticRetinopathy #eyescreening

The Latest report released by @IDF shows that as of 2021, 20'300 people suffered from #Diabetes in the Curacao. As Diabetic Retinopathy (DR) is a highly prevalent eye condition among diabetic patients, its early detection is crucial in order to initiate a timely treatment and prevent further vision deterioration and potentially even blindness. To overcome the limited accessibility to specialized eye care points, we have partnered with @LabdeMED to bring preventive #DR screening to all inhabitants of the Curacao island, including remote rural areas. Our #ArtificialIntelligence powered software, #RetCAD allows mobile teams to quickly and automatically analyze large numbers of fundus eye images of diabetic patients, providing on the spot assessment of the DR presence. To know more about this and other projects to support DR diagnosis with Artificial Intelligence, visit: https://lnkd.in/eRGE-jdq #RetCAD #AI #eyescreening #DiabeticRetinopathy

Timely treatment is crucial to prevent severe vision complications and even blindness for people suffering from Diabetic Retinopathy (DR). But delayed diagnosis and increasing patient loads in opthalmology clinic pose challenges. DR is a significant concern among diabetic patients. In the Netherlands, 1.1 million individuals are living with diabetes, with 10-15% of them affected by DR. To tackle these large numbers and clinical workload, we have partnered with leading Dutch hospitals like Jeroen Bosch Ziekenhuis and Gelre ziekenhuizen to enable faster and more efficient patient care. Our Artificial Intelligence Software, RetCAD seamlessly integrates into clinical workflows, allowing ophthalmologists to reduce diagnostic lead times and enhancing the triaging process. To know more about RetCAD and other international project implementations, visit: retcad.eu #AI #RetCAD #DiabeticRetinopathy #eyescreening

The latest reports released by World Health Organization (WHO) indicate that #Glaucoma is one of the leading causes in vision impairment and blindness. The disease is characterized by damage to the optic nerve as a result of high-pressure development in the eye. Several studies show that patients diagnosed with Glaucoma have not reported prior warning signs. The earliest possible detection thus is crucial for initiating a timely treatment. Visit: retcad.eu to learn more on our #RetCAD software, providing AI-enabled automatic analysis of fundus images for detection of early signs of Glaucoma. #RetCAD #AI #glaucoma #visionhealth

Our Artificial Intelligence (AI) based Software RetCAD™, supporting efficient and effective Diabetic Retinopathy and Age-Related Macular Degeneration Diagnosis, has shown potential in detecting possible clinical ocular biomarkers in incidental diseases such as hypertensive retinopathy. In a study conducted at Dobney Hypertension Centre, Western Australia between 2018 and 2022, the fundus images of 433 patients with treatment-resistant hypertension were analyzed using 3 deep learning algorithms and RetCAD™ was one among them. The study illustrates that AI solutions such as RetCAD™ can add clinical value in other retinal diseases by capturing more biomarkers for incidental diseases. This suggests a strong potential in other ocular clinical applications. To know more about this study's results, check out the paper published in Nature Journal: https://lnkd.in/eYxfhhjt #RetCAD #AI #Retina #VisionHealth

Telemedicine, mobile hand-held fundus cameras, and AI-powered automated algorithms have the potential to improve the efficacy of Diabetic Retinopathy (DR) screening programs. It is estimated that by 2045, globally, 783 million people will suffer from Diabetes. DR is a major complication of Diabetes and can lead to irreversible vision loss and blindness. Early diagnosis and on-time treatment can support the prevention of developing sight threatening DR. In Finland, successful National DR Screening Programs have been implemented utilizing the power of telemedicine in the country’s rural areas as well. In the recent study conducted at Oulu University Hospital, 156 patients suffering from Type 1 and Type 2 Diabetes were recruited for non-referrable and referrable DR identification. 1248 fundus images of these patients were captured using the non-mydriatic handheld fundus camera #OptomedAurora by Optomed Plc . Our Artificial Intelligence (AI) -based Software, RetCAD™ was one among the 21 AI analytics software used in combination with this fundus camera to screen for DR. The results of this study showed that the mean values of sensitivity and specificity was 77.5% and 80.6 percent respectively. This study iterates the strong potential of DR screening using hand-held fundus cameras and AI-based algorithms. To read more about this study, check out: Comparison of 21 artificial intelligence algorithms in automated diabetic retinopathy screening using handheld fundus camera, available on: https://lnkd.in/eK8vkDgD #RetCAD #AI #DiabeticRetinopathy #VisionHealth

RETC

EU:RETCAD

Thirona Retina

Financials Not Available